Serb SA   Report issue

For profit Phase 4
Founded: Brussels Belgium (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2017
NCT03080558
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Laboratoire SERB | SERB SA

Active Ingredients

Marketed Drugs (1)

hydroxocobalamin (cyanokit) (2006)

Drugs in Phase 4 Trials (1)

indocyanine green (ic-green) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Endometriosis (Phase 4)

Neovascularization, Pathologic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1